Crescent Enterprises and Dr. Fred Moll, the company’s board chair and the man labeled “the father of surgical robotics,” co-led the round. It brings the Houston-based company’s total funding to $92 million since inception.
XCath said the new funds support its effort to bring its endovascular robot to the market as it seeks to deliver clinical telerobotic mechanical thrombectomy procedures.
The company reported the first-in-human use of its Iris endovascular robotic system in November 2025. It reported the use of the Iris platform to treat three patients with complex brain aneurysms.
Endovascular robotics is an interesting space to watch, as companies like Microbot Medical and Sentante also develop endovascular robotic systems.
XCath said its first-in-human procedures marked the second time in history that a surgical robot was used in an intracranial neurovascular intervention.
The company says Iris represents the only endovascular robotic system currently in development to achieve intracranial navigation or neurointerventional treatment. It also labeled it the only robot in the world to perform an intracranial neurovascular procedure involving the robotic manipulation of three devices and the only system to have operated using standard monoplane imaging equipment.
Commentary from XCath officials and board members
Eduardo Fonseca, CEO of XCath, said:
“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases. In 2025 the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”
Dr. Fred Moll said:
“Robotic surgery succeeds when innovation is paired with practical execution. XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”
Neeraj Agrawal, XCath board member and Crescent Enterprises executive director, said:
“Surgical robotics represents one of the most compelling long-term investment opportunities in healthcare. XCath has assembled an exceptional team of physicians, entrepreneurs and engineers, clearly focused on addressing a significant global healthcare unmet need.”
Nicholas Drysdale, XCath CFO, said:
“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems. With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics.”
